The changing incidence of thyroid cancer

Nature Reviews Endocrinology

Volumn 12, Issue 11, 2016, Pages 646-653

  Kitahara, Cari M ^a   Sosa, Julie A ^b,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABLATION THERAPY; AGE; BODY HEIGHT; CANCER INCIDENCE; DISEASE SPECIFIC SURVIVAL; ETHNICITY; FAMILY HISTORY; HEALTH CARE COST; HORMONE SUBSTITUTION; HUMAN; IONIZING RADIATION; LONG TERM SURVIVAL; LYMPH NODE DISSECTION; OBESITY; OVERALL SURVIVAL; OVERDIAGNOSIS; PAPILLARY THYROID MICROCARCINOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION EXPOSURE; RADIOACTIVE IODINE ABLATION; REVIEW; SEX; SMOKING; SUBTOTAL THYROIDECTOMY; THYROID CANCER; THYROIDECTOMY; ADENOCARCINOMA, FOLLICULAR; AGE DISTRIBUTION; CARCINOMA; CARCINOMA, NEUROENDOCRINE; DIAGNOSTIC IMAGING; FINE NEEDLE ASPIRATION BIOPSY; HEALTH SERVICE; INCIDENCE; PATHOLOGY; RISK FACTOR; SEX RATIO; STATISTICS AND NUMERICAL DATA; THYROID CARCINOMA, ANAPLASTIC; THYROID NEOPLASMS; THYROID NODULE; UNITED STATES;

ADENOCARCINOMA, FOLLICULAR; AGE DISTRIBUTION; BIOPSY, FINE-NEEDLE; CARCINOMA; CARCINOMA, NEUROENDOCRINE; HUMANS; INCIDENCE; MEDICAL OVERUSE; OBESITY; RADIATION EXPOSURE; RISK FACTORS; SEX DISTRIBUTION; SMOKING; THYROID CARCINOMA, ANAPLASTIC; THYROID NEOPLASMS; THYROID NODULE; UNITED STATES;

EID: 84978511652     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2016.110     Document Type: Review

References (106)

1. Ferlay, J. et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. World Health Organization http://globocan. iarc.fr/Pages/summary-table-pop-prev-sel.aspx (2013).
2. Ron, E. & Schneider, A. B. in Cancer Epidemiology and Prevention (eds Schottenfeld, D. & Fraumeni, J. F. Jr) 975-994 (Oxford University Press, 2006).
3. Kilfoy, B. A. et al. International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control 20, 525-531 (2009).
4. Enewold, L. et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005.
5. Kent, W. D. et al. Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. CMAJ 177, 1357-1361 (2007).
6. Liu, S., Semenciw, R., Ugnat, A. M. & Mao, Y. Increasing thyroid cancer incidence in Canada, 1970-1996: time trends and age-period-cohort effects. Br. J. Cancer 85, 1335-1339 (2001).
7. Uhry, Z. et al. Estimating infra-national and national thyroid cancer incidence in France from cancer registries data and national hospital discharge database. Eur. J. Epidemiol. 22, 607-614 (2007).
8. Colonna, M. et al. Recent trends in incidence, geographical distribution, and survival of papillary thyroid cancer in France. Cancer Epidemiol. 39, 511-518 (2015).
9. Reynolds, R. M. et al. Changing trends in incidence and mortality of thyroid cancer in Scotland. Clin. Endocrinol. (Oxf.) 62, 156-162 (2005).
10. Smailyte, G., Miseikyte-Kaubriene, E. & Kurtinaitis, J. Increasing thyroid cancer incidence in Lithuania in 1978-2003. BMC Cancer 6, 284 (2006).
11. Pandeya, N. et al. Increasing thyroid cancer incidence in Queensland, Australia 1982-2008- true increase or overdiagnosis? Clin. Endocrinol. (Oxf.) http://dx.doi. org/10.1111/cen.12724 (2015).
12. Keinan-Boker, L. & Silverman, B. G. Trends of thyroid cancer in Israel: 1980-2012. Rambam Maimonides Med. J. 7, e0001 (2016).
13. Lubina, A. et al. Time trends of incidence rates of thyroid cancer in Israel: what might explain the sharp increase. Thyroid 16, 1033-1040 (2006).
14. Wang, Y. & Wang, W. Increasing incidence of thyroid cancer in Shanghai, China, 1983-2007. Asia Pac. J. Public Health 27, NP223-NP229 (2015).
15. Ahn, H. S., Kim, H. J. & Welch, H. G. Korea?s thyroidcancer ?epidemic?- screening and overdiagnosis. N. Engl. J. Med. 371, 1765-1767 (2014).
16. Veiga, L. H., Neta, G., Aschebrook-Kilfoy, B., Ron, E. & Devesa, S. S. Thyroid cancer incidence patterns in Sao Paulo, Brazil, and the U.S. SEER program, 1997-2008. Thyroid 23, 748-757 (2013).
17. Howlader, N. et al. SEER Cancer Statistics Review, 1975-2012. National Cancer Institute http://seer. cancer.gov/csr/1975-2012 (2015).
18. Ito, Y., Nikiforov, Y. E., Schlumberger, M. & Vigneri, R. Increasing incidence of thyroid cancer: controversies explored. Nat. Rev. Endocrinol. 9, 178-184 (2013).
19. Brito, J. P. & Davies, L. Is there really an increased incidence of thyroid cancer? Curr. Opin. Endocrinol. Diabetes Obes. 21, 405-408 (2014).
20. Davies, L. & Welch, H. G. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295, 2164-2167 (2006).
21. Franceschi, S. & Vaccarella, S. Thyroid cancer: an epidemic of disease or an epidemic of diagnosis? Int. J. Cancer 136, 2738-2739 (2015).
22. Morris, L. G., Tuttle, R. M. & Davies, L. Changing trends in the incidence of thyroid cancer in the United States. JAMA Otolaryngol. Head Neck Surg. http:// dx.doi.org/10.1001/jamaoto.2016.0230 (2016).
23. Aschebrook-Kilfoy, B. & Grogan, R. H. Re: Brito et al. overdiagnosis of thyroid cancer and Graves? disease. Thyroid 24, 403-404 (2014).
24. Sosa, J. A., Hanna, J. W., Robinson, K. A. & Lanman, R. B. Increases in thyroid nodule fine-needle aspirations, operations, and diagnoses of thyroid cancer in the United States. Surgery 154, 1420-1426; discussion 1426-1427 (2013).
25. Guth, S., Theune, U., Aberle, J., Galach, A. & Bamberger, C. M. Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination. Eur. J. Clin. Invest. 39, 699-706 (2009).
26. Uppal, A. et al. Benign and malignant thyroid incidentalomas are rare in routine clinical practice: a review of 97,908 imaging studies. Cancer Epidemiol. Biomarkers Prev. 24, 1327-1331 (2015).
27. Burgess, J. R. Temporal trends for thyroid carcinoma in Australia: an increasing incidence of papillary thyroid carcinoma (1982-1997). Thyroid 12, 141-149 (2002).
28. Piersanti, M., Ezzat, S. & Asa, S. L. Controversies in papillary microcarcinoma of the thyroid. Endocr. Pathol. 14, 183-191 (2003).
29. Martinez-Tello, F. J., Martinez-Cabruja, R., Fernandez- Martin, J., Lasso-Oria, C. & Ballestin-Carcavilla, C. Occult carcinoma of the thyroid. A systematic autopsy study from Spain of two series performed with two different methods. Cancer 71, 4022-4029 (1993).
30. Ross, D. S. & Tuttle, R. M. Observing micopapillary thyroid cancers. Thyroid 24, 3-6 (2014).
31. Schneider, A. B. et al. Thyroid nodules in the follow-up of irradiated individuals: comparison of thyroid ultrasound with scanning and palpation. J. Clin. Endocrinol. Metab. 82, 4020-4027 (1997).
32. Zhu, C. et al. A birth cohort analysis of the incidence of papillary thyroid cancer in the United States, 1973-2004. Thyroid 19, 1061-1066 (2009).
33. Horn-Ross, P. L. et al. Continued rapid increase in thyroid cancer incidence in California: trends by patient, tumor, and neighborhood characteristics. Cancer Epidemiol. Biomarkers Prev. 23, 1067-1079 (2014).
34. Meinhold, C. L. et al. Nonradiation risk factors for thyroid cancer in the US Radiologic Technologists Study. Am. J. Epidemiol. 171, 242-253 (2010).
35. Sen, A. et al. Baseline and lifetime alcohol consumption and risk of differentiated thyroid carcinoma in the EPIC study. Br. J. Cancer 113, 840-847 (2015).
36. Zamora-Ros, R. et al. Energy and macronutrient intake and risk of differentiated thyroid carcinoma in the European Prospective Investigation into Cancer and Nutrition study. Int. J. Cancer 138, 65-73 (2016).
37. Rinaldi, S. et al. Thyroid-stimulating hormone, thyroglobulin, and thyroid hormones and risk of differentiated thyroid carcinoma: the EPIC study. J. Natl Cancer Inst. 106, dj097 (2014).
38. Braganza, M. Z. et al. Adolescent and mid-life diet and subsequent risk of thyroid cancer in the NIH-AARP Diet and Health Study. Int. J. Cancer 137, 2413-2423 (2015).
39. Balasubramaniam, S., Ron, E., Gridley, G., Schneider, A. B. & Brenner, A. V. Association between benign thyroid and endocrine disorders and subsequent risk of thyroid cancer among 4.5 million U.S. male veterans. J. Clin. Endocrinol. Metab. 97, 2661-2669 (2012).
40. Almquist, M. et al. Metabolic factors and risk of thyroid cancer in the Metabolic syndrome and Cancer project (Me-Can). Cancer Causes Control 22, 743-751 (2011).
41. Luo, J., Phillips, L., Liu, S., Wactawski-Wende, J. & Margolis, K. L. Diabetes, diabetes treatment, and risk of thyroid cancer. J. Clin. Endocrinol. Metab. 101, 1243-1248 (2016).
42. Schmid, D., Behrens, G., Jochem, C., Keimling, M. & Leitzmann, M. Physical activity, diabetes, and risk of thyroid cancer: a systematic review and meta-analysis. Eur. J. Epidemiol. 28, 945-958 (2013).
43. Cho, Y. A. & Kim, J. Thyroid cancer risk and smoking status: a meta-analysis. Cancer Causes Control 25, 1187-1195 (2014).
44. Caini, S. et al. Menstrual and reproductive history and use of exogenous sex hormones and risk of thyroid cancer among women: a meta-analysis of prospective studies. Cancer Causes Control 26, 511-518 (2015).
45. Jing, Z. et al. Association between height and thyroid cancer risk: a meta-analysis of prospective cohort studies. Int. J. Cancer 137, 1484-1490 (2015).
46. Schmid, D., Ricci, C., Behrens, G. & Leitzmann, M. F. Adiposity and risk of thyroid cancer: a systematic review and meta-analysis. Obes. Rev. 16, 1042-1054 (2015).
47. Patel, D. et al. Thyroid cancer and nonsteroidal antiinflammatory drug use: a pooled analysis of patients older than 40 years of age. Thyroid 25, 1355-1362 (2015).
48. Kitahara, C. M. et al. Physical activity, diabetes, and thyroid cancer risk: a pooled analysis of five prospective studies. Cancer Causes Control http://dx. doi.org/10.1007/s10552-012-9896-y (2012).
49. Kitahara, C. M. et al. Cigarette smoking, alcohol intake, and thyroid cancer risk: a pooled analysis of five prospective studies in the United States. Cancer Causes Control 23, 1615-1624 (2012).
50. Kitahara, C. M. et al. Anthropometric factors and thyroid cancer risk by histological subtype: pooled analysis of 22 prospective studies. Thyroid 26, 306-318 (2016).
51. Aschebrook-Kilfoy, B., Kaplan, E. L., Chiu, B. C., Angelos, P. & Grogan, R. H. The acceleration in papillary thyroid cancer incidence rates is similar among racial and ethnic groups in the United States. Ann. Surg. Oncol. 20, 2746-2753 (2013).
52. Dal Maso, L., Bosetti, C., La Vecchia, C. & Franceschi, S. Risk factors for thyroid cancer: an epidemiological review focused on nutritional factors. Cancer Causes Control 20, 75-86 (2009).
53. Furukawa, K. et al. Long-term trend of thyroid cancer risk among Japanese atomic-bomb survivors: 60 years after exposure. Int. J. Cancer 132, 1222-1226 (2013).
54. Sinnott, B., Ron, E. & Schneider, A. B. Exposing the thyroid to radiation: a review of its current extent, risks, and implications. Endocr. Rev. 31, 756-773 (2010).
55. Ron, E. et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat. Res. 141, 259-277 (1995).
56. National Council on Radiation Protection and Measurements. NCRP Report No. 160, Ionizing Radiation Exposure of the Population of the United States (NCRP, 2009).
57. Pellegriti, G., Frasca, F., Regalbuto, C., Squatrito, S. & Vigneri, R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J. Cancer Epidemiol. 2013, 965212 (2013).
58. Schonfeld, S. J., Lee, C. & Berrington de Gonzalez, A. Medical exposure to radiation and thyroid cancer. Clin. Oncol. (R. Coll. Radiol.) 23, 244-250 (2011).
59. Hamatani, K. et al. RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose. Cancer Res. 68, 7176-7182 (2008).
60. Nikiforov, Y. E., Rowland, J. M., Bove, K. E., Monforte- Munoz, H. & Fagin, J. A. Distinct pattern of ret oncogene rearrangements in morphological variants of radiationinduced and sporadic thyroid papillary carcinomas in children. Cancer Res. 57, 1690-1694 (1997).
61. Ciampi, R. & Nikiforov, Y. E. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 148, 936-941 (2007).
62. Fugazzola, L. et al. Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Res. 55, 5617-5620 (1995).
63. Elisei, R. et al. BRAFV600E mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J. Clin. Endocrinol. Metab. 93, 3943-3949 (2008).
64. Collins, B. J., Schneider, A. B., Prinz, R. A. & Xu, X. Low frequency of BRAF mutations in adult patients with papillary thyroid cancers following childhood radiation exposure. Thyroid 16, 61-66 (2006).
65. Xing, M. BRAF mutation in thyroid cancer. Endocr. Relat. Cancer 12, 245-262 (2005).
66. Romei, C. et al. Modifications in the papillary thyroid cancer gene profile over the last 15 years. J. Clin. Endocrinol. Metab. 97, E1758-E1765 (2012).
67. Jung, C. K. et al. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J. Clin. Endocrinol. Metab. 99, E276-E285 (2014).
68. Kebebew, E. et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann. Surg. 246, 466-470; discussion 470-471 (2007).
69. Mathur, A. et al. Higher rate of BRAF mutation in papillary thyroid cancer over time: a single-institution study. Cancer 117, 4390-4395 (2011).
70. Brignardello, E. et al. Ultrasound screening for thyroid carcinoma in childhood cancer survivors: a case series. J. Clin. Endocrinol. Metab. 93, 4840-4843 (2008).
71. Acharya, S. et al. Thyroid neoplasms after therapeutic radiation for malignancies during childhood or adolescence. Cancer 97, 2397-2403 (2003).
72. Crom, D. B. et al. Ultrasonography for thyroid screening after head and neck irradiation in childhood cancer survivors. Med. Pediatr. Oncol. 28, 15-21 (1997).
73. Ng, M. et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384, 766-781 (2014).
74. Tresallet, C. et al. The incidence of papillary thyroid carcinoma and outcomes in operative patients according to their body mass indices. Surgery 156, 1145-1152 (2014).
75. Kim, H. J. et al. Associations between body mass index and clinico-pathological characteristics of papillary thyroid cancer. Clin. Endocrinol. (Oxf.) 78, 134-140 (2013).
76. Choi, J. S., Kim, E. K., Moon, H. J. & Kwak, J. Y. Higher body mass index may be a predictor of extrathyroidal extension in patients with papillary thyroid microcarcinoma. Endocrine 48, 264-271 (2015).
77. Kitahara, C. M., Gamborg, M., Berrington de Gonzalez, A., Sorensen, T. I. & Baker, J. L. Childhood height and body mass index were associated with risk of adult thyroid cancer in a large cohort study. Cancer Res. 74, 235-242 (2014).
78. Pazaitou-Panayiotou, K., Polyzos, S. A. & Mantzoros, C. S. Obesity and thyroid cancer: epidemiologic associations and underlying mechanisms. Obes. Rev. 14, 1006-1022 (2013).
79. Kim, W. G., Park, J. W., Willingham, M. C. & Cheng, S. Y. Diet-induced obesity increases tumor growth and promotes anaplastic change in thyroid cancer in a mouse model. Endocrinology 154, 2 936-2947 (2013).
80. Ng, M. et al. Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA 311, 183-192 (2014).
81. Wiersinga, W. M. Smoking and thyroid. Clin. Endocrinol. (Oxf.) 79, 145-151 (2013).
82. Zimmermann, M. B. & Galetti, V. Iodine intake as a risk factor for thyroid cancer: a comprehensive review of animal and human studies. Thyroid Res. 8, 8 (2015).
83. Blomberg, M., Feldt-Rasmussen, U., Andersen, K. K. & Kjaer, S. K. Thyroid cancer in Denmark 1943-2008, before and after iodine supplementation. Int. J. Cancer 131, 2360-2366 (2012).
84. Levin, M. L. The occurrence of lung cancer in man. Acta Unio Int. Contra Cancrum 9, 531-541 (1953).
85. Ogden, C. L., Carroll, M. D., Kit, B. K. & Flegal, K. M. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 311, 806-814 (2014).
86. National Center for Health Statistics. Early release of selected estimates based on data from the National Health Interview Survey, 2014. Centers for Disease Control and Prevention http://www.cdc.gov/nchs/ fastats/smoking.htm (2016).
87. Zagzag, J. et al. Method of detection of welldifferentiated thyroid cancers in obese and non-obese patients. PLoS ONE 11, e0152768 (2016).
88. Loeb, S. et al. Overdiagnosis and overtreatment of prostate cancer. Eur. Urol. 65, 1046-1055 (2014).
89. Sugitani, I. et al. Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J. Surg. 34, 1222-1231 (2010).
90. Wang, T. S., Goffredo, P., Sosa, J. A. & Roman, S. A. Papillary thyroid microcarcinoma: an over-treated malignancy? World J. Surg. 38, 2297-2303 (2014).
91. Giordano, D. et al. Complications of central neck dissection in patients with papillary thyroid carcinoma: results of a study on 1087 patients and review of the literature. Thyroid 22, 911-917 (2012).
92. Applewhite, M. K. et al. Quality of life in thyroid cancer is similar to that of other cancers with worse survival. World J. Surg. 40, 551-561 (2016).
93. Ramsey, S. et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff. (Millwood) 32, 1143-1152 (2013).
94. Lubitz, C. C. et al. Annual financial impact of welldifferentiated thyroid cancer care in the United States. Cancer 120, 1345-1352 (2014).
95. Aschebrook-Kilfoy, B. et al. The clinical and economic burden of a sustained increase in thyroid cancer incidence. Cancer Epidemiol. Biomarkers Prev. 22, 1252-1259 (2013).
96. Cooper, D. S. et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16, 109-142 (2006).
97. Hoang, J. K. et al. Managing incidental thyroid nodules detected on imaging: white paper of the ACR Incidental Thyroid Findings Committee. J. Am. Coll. Radiol. 12, 143-150 (2015).
98. Haugen, B. R. et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1-133 (2016).
99. Cooper, D. S. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167-1214 (2009).
100. Ito, Y. et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J. Surg. 34, 28-35 (2010).
101. Ito, Y. et al. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid 24, 27-34 (2014).
102. Shrestha, R. T., Karunamurthy, A., Amin, K., Nikiforov, Y. E. & Caramori, M. L. Multiple mutations detected preoperatively may predict aggressive behavior of papillary thyroid cancer and guide management- a case report. Thyroid 25, 1375-1378 (2015).
103. Nikiforova, M. N., Wald, A. I., Roy, S., Durso, M. B. & Nikiforov, Y. E. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J. Clin. Endocrinol. Metab. 98, E1852-E1860 (2013).
104. Edge, S. B. et al. (eds) AJCC Cancer Staging Manual 7th edn 59-64 (Springer-Verlag, 2010).
105. Adam, M. A. et al. Presence and number of lymph node metastases are associated with compromised survival for patients younger than age 45 years with papillary thyroid cancer. J. Clin. Oncol. 33, 2370-2375 (2015).
106. Nikiforov, Y. E. et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol. http://dx.doi. org/10.1001/jamaoncol.2016.0386 (2016).